Company profile: Cognition Therapeutics
1.1 - Company Overview
Company description
- Provider of neurodegenerative disease therapeutics, developing CT1812, an oral sigma-2 receptor-targeting therapy aimed at slowing progression of Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration. The company conducts clinical trials on CT1812's safety and efficacy and researches sigma-2 receptor modulators to restore neuronal responses and prevent/displace toxic protein buildup in neurons.
Products and services
- Clinical Trials for Neurodegenerative Diseases: Executes multi-indication clinical studies of CT1812 across Alzheimer’s disease, dementia with Lewy bodies, and dry AMD, rigorously evaluating safety and efficacy
- CT1812: An oral therapy in development to slow progression of Alzheimer’s disease, dementia with Lewy bodies, and dry AMD by targeting the sigma-2 receptor
- Sigma-2 Receptor Modulation: Target-specific research on sigma-2 receptor modulators to restore damaged responses in neurodegenerative diseases, preventing and displacing toxic protein buildup in neurons
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cognition Therapeutics
Durin Technologies
HQ: United States
Website
- Description: Provider of blood-based diagnostic tests and a multi-disease platform for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, that detect disease-specific autoantibodies in serum for early detection and diagnosis, and for monitoring disease progression by tracking changes in autoantibody profiles over time.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Durin Technologies company profile →
Opiant Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical treatments for drug overdose and addictions, leveraging intranasal and injectable delivery technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Opiant Pharmaceuticals company profile →
Aruna Bio
HQ: United States
Website
- Description: Provider of neural exosome-based therapies for central nervous system and neurodegenerative disorders; developer of AB126, a therapeutic neural cell-derived exosome that crosses the blood-brain barrier to reduce neuro-inflammation, promote neuro-protection, and stimulate neuro-regeneration, plus a CNS therapeutic platform and pipeline; also conducts research in stem cells, neural stem cells, and drug toxicity assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aruna Bio company profile →
Neumora
HQ: United States
Website
- Description: Provider of clinical-stage investigational therapies for brain diseases, conducting trials to evaluate new treatments. Portfolio includes navacaprant, an investigational oral Phase 3 medication for major depressive disorder that modulates dopamine and reward processing pathways, plus NMRA-NLRP3 and NMRA-GCASE programs for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neumora company profile →
Annexon Biosciences
HQ: United States
Website
- Description: Provider of complement-targeting therapeutics focused on C1q, including ANX005 to inhibit the classical complement pathway for autoimmune and neurodegenerative disorders; ANX007, an intravitreal therapy for glaucoma and other ophthalmic conditions; ANX009, a subcutaneous therapy for systemic autoimmune diseases; and ANX1502, an early-stage candidate for complement-mediated diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annexon Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cognition Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cognition Therapeutics
2.2 - Growth funds investing in similar companies to Cognition Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cognition Therapeutics
4.2 - Public trading comparable groups for Cognition Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →